We discuss various strategies for treatment pauses in management of neovascular AMD, differences between bevacizumab and aflibercept in patients who can be successfully paused, and intra ocular biomarkers that may identify eyes in which treatment may be successful paused with Dr. Akrit Sodhi, Associate Professor of Ophthalmology, Johns Hopkins University School of Medicine, Wilmer Eye Institute.
We review the current status of gene therapy for inherited retinal disorders, discussing preoperative evaluation, surgery, and follow up with Dr. Ninel Gregori, Professor of Clinical Ophthalmology, University of Miami Miller School of Medicine, Bascom Palmer Eye Institute.
We discuss the use of a suprachoroidal delivery system for delivery of tryrosinase kinase inhibitor for the treatment of neovascular AMD with Dr. Thomas Ciulla, Chief Development Officer, Chief Medical Officer, Clearside Biomedical.
We discuss a phase 2/3 trial employing tarcocimab reformer for branch and central vein occlusion with Michael Singer, MD, Clinical Professor University of Texas San Antonio Health Sciences Center.
We discuss the use of intravitreal avacincaptad peg for the treatment of geographic atrophy in two randomized trials, Gather 1 and Gather 2 with Dr. Arshad Khanani, Sierra Eye Associates, Reno Nevada and Associate Clinical Professor University of Nevada Reno.
We discuss the role that en-face optical coherence tomography (OCT) can play in understanding the evolution of intermediate AMD and geographic atrophy with Dr. Philip Rosenfeld, Professor of Ophthalmology, Bascom Palmer Eye Institute and the University of Miami Miller School of Medicine.
We review the 24 month results of the Derby and Oaks trials, with emphasis on the safety of pegcetcoplan with Caroline Baumal, MD, Professor of Ophthalmology Tufts University School of Medicine and the New England Eye Center.
Dr. Dennis Marcus, Clinical Professor of Ophthalmology, Medical College of Georgia at Augusta University discusses the value of ultra wide field imaging in assessing diabetic retinopathy worsening over time.
Dr. Michael Elman of Elman Retina Group, Baltimore, Maryland, presents 10 year data demonstrating that Preferential Hyperacuity Perimetry (the Foresee Device) is a valuable tool in early detection of neovascular AMD.
Dr. Susanna Park reviews current therapy of retinal branch and central vein occlusion and discusses a Phase I trial (the TRUST study) investigating the use of intravitreal autologous stem cells as a possible treatment for central vein occlusion. Dr. Susanna Park, Professor of Ophthalmology, Roth Endowed Chair in Visual Science at the University of California, Davis
We discuss a novel mechanism of action for the treatment of diabetic macular edema and neovascular AMD with Phase I/II trial results Dr. Raj Maturi, Midwest Eye Institute, Indiana University School of Medicine.
We review lesion progression in the eighteen month data with Roger Goldberg, MD, MBA of Bay Area Retina Associates, Walnut Creek, California.
We discuss the role that clinicians can play in fostering innovation in the retinal pharmacotherapy space with Dr. Eliot Lazar.
We discuss the 12 month results of the Phase I Davio Trial of an innovative TKI agent for the sustained treatment of neovascular AMD with Dr. Rishi Singh, Professor of Ophthalmology, Cole Eye Insitute, President, Cleveland Cllinic-Martin Hospital, Stuart, Florida.
We discuss treat and extend versus alternate dosing strategies to treat center involving diabetic macular edema with Dr. Varun Chaudhary, Chief of Ophthalmology, Hamilton Regional Eye Center and Professor, McMaster University.
We discuss the role of IOP pressure elevation following intravitreal anti-VEGF therapy with Parnian Arjmand, MD, MSC, FCSRS of the Toronto Retina Institute.
We discuss real world experience about faricimab with Dr. Carl Danzig of Pompano Beach, Florida.
We discuss new treatment options and clinical trials for radiation retinopathy with Prithvi Mruthyunjaya MD Professor of Ophthalmology, Stanford Medical School, Director of Ocular Oncology, Byers Eye Institute.
We discuss new developments in gene therapy for inherited retinal diseases with Sue Washer, President and CEO of AGTC.
We discuss a novel strategy using RNA anti sense technology for treating geographic atrophy with Dr. Nik London, San Diego, California.
We discuss the 18 month results of the Derby and Oaks trials of pegcetacoplan for treatment of geographic atrophy with Roger Goldberg, MD of Walnut Creek, California.
We discuss a new retinal sealant that may replace the need for tamponade with expansile gas or silicone oil with Dr. James Anthony Stefater.
We discuss how new developments in imaging and therapeutics have impacted the treatment of sickle cell retinopathy with Dr. Adrienne Scott, Professor of Ophthalmology at Johns Hopkins and the Wilmer Eye Institute.
We discuss the results of a Phase II clinical trail studying the efficacy of high dose aflibercept (8mg) for treating neovascular AMD with Dr. David Brown of Retina Consultants of Texas in Houston.
We discuss new developments in the diagnosis and therapy of choroidal melanoma with Dr. Paul Finger, Clinical Professor, NYU and Chair, Eye Cancer Foundation.
We discuss the two year results of a Phase I/II trial of a stem cell implant for the treatment of geographic atrophy with Dr. Amir Kashani, Associate Professor, Wilmer Eye Institute.
We discuss the one year results of the DERBY and OAKs studies treating geographic atrophy with Dr. David Lally, Assistant Professor University of Massachusetts and Tufts University.
We discuss the use of deep learning techniques in the detection and management of macular degeneration with Dr. Pearse Keane, Consultant Moorfields Eye Hospital, Professor of Artificial Medical Intelligence University College London.
In our latest update, We discuss the use of APX3330 a novel oral agent for the treatment of diabetic retinopathy with Dr. David Boyer, Retina Vitreous Associates, Adjunct Professor USC Roski Eye Institute.
We discuss the use of a home based OCT system with artificial intelligence to monitor the treatment of neovascular AMD with Dr. Nancy Holekamp, Professor of Clinical Ophthalmology, Washington University School of Medicine.
